Global Media Contacts:
Christine Lydon
+44-20-7395-7145
christine.lydon@fleishmaneurope.com
Iva Ng
OrbusNeich
+852 3109-7268
ing@orbusneich.com

COMBO™ Dual Therapy Stent – Three-year Data featured at JIM 2015

Data supports healing benefits of world's only Dual Therapy Stent

Rome, Italy [13 February 2015] A three-year review of data on the COMBO Dual Therapy Stent was presented at the Joint Interventional Meeting (JIM) 2015 in Rome. These data demonstrate the excellent healing benefits of the COMBO Dual Therapy Stent in the treatment of coronary artery disease in the short, medium and long-term.

The COMBO Dual Therapy Stent's unique endothelial progenitor cell (EPC) capture technology combined with abluminal drug delivery accelerates the natural healing of the vessel wall and provides key clinical benefits throughout the healing process. The COMBO Dual Therapy Stent is recognized in the latest ESC/EACT guidelines on Myocardial Revascularization.

Professor Corrado Tamburino of Ferrarotto Hospital, Catania, Italy, presented results from the REMEDEE First In Man (FIM) and EGO COMBO trials, which monitored stent healing using optical coherence tomography (OCT), the highest resolution equipment available in the clinic. Stent coverage and neo-intimal thickness were evaluated, two important measures from which healing can be assessed.

In the short term, rapid strut coverage was shown from as early as two months; mid-term, neo-intimal proliferation was controlled and low rates of restenosis were reported, comparable to contemporary Drug Eluting Stents; and in the long-term, researchers reported stable and consistent healing, lower neo-intimal thickness compared with the other stent groups, and the absence of neoatherosclerosis.

"The consistent data on the COMBO technology is promising," said Professor Tamburino. "What we have seen to date reflects what is being reported in clinical practice and the real-life difference it is making to the lives of patients. We look forward to seeing the results of the all of the COMBO clinical trial programs which include over 5,500 patients."

Dr Tim Kinnaird, University Hospital of Wales, Cardiff, UK, compared IVUS-VH (virtual histology intravascular ultrasound) with OCT imaging processes in a presentation entitled 'Can Imaging Differentiate Dual Therapy Stent from Mono-therapy DES?'

"Advancements in imaging provide us with the opportunity to have new insights into stents," said Dr Kinnaird. "These advancements give us the opportunity to appreciate the advanced healing offered by COMBO with its unique endothelial progenitor cell (EPC) capture technology, which translates to true vessel healing, compared with conventional monotherapy drug eluting stents."

The COMBO Stent featured in live cases transmitted from the Columbus Hospital in Milano, Italy and Bonn University Hospital in Bonn, Germany. From the Columbus University, the patient presented with a multi-vessel disease, a history of atrial fibrillation and impaired left ventricular function. A long, calcified and diffusely diseased left anterior descending artery was treated with COMBO stents. From the Bonn University Hospital, the patient, a 67 year old male with a history of type II diabetes, hypertension and a poor AF was treated with a COMBO Stent. Both cases were successful.

COMBO Dual Therapy Stent - Repair, Regenerate, Naturally

COMBO is the world's first and only dual therapy stent designed to repair vessel injury and regenerate endothelium, fostering natural, true vessel healing. It does this by accelerating endothelial coverage and controlling neo-intimal proliferation. This is done through a combination of the proven EPC capturing technology and a sirolimus drug elution, delivered from a bioresorbable polymer that is completely degraded within 90 days.

OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world's first pro-healing stent, the Genous™ Stent. Other products include stents and balloons marketed under the names of Azule™, R Stent™, Scoreflex™, Sapphire™, Sapphire™, II and Sapphire™ II NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

###